HRP20140257T1 - Uporaba ciklesonida za lijeäśenje bolesti dišnih puteva - Google Patents
Uporaba ciklesonida za lijeäśenje bolesti dišnih puteva Download PDFInfo
- Publication number
- HRP20140257T1 HRP20140257T1 HRP20140257TT HRP20140257T HRP20140257T1 HR P20140257 T1 HRP20140257 T1 HR P20140257T1 HR P20140257T T HRP20140257T T HR P20140257TT HR P20140257 T HRP20140257 T HR P20140257T HR P20140257 T1 HRP20140257 T1 HR P20140257T1
- Authority
- HR
- Croatia
- Prior art keywords
- use according
- ciclesonide
- drug
- respiratory tract
- dose
- Prior art date
Links
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 title claims 12
- 229960003728 ciclesonide Drugs 0.000 title claims 12
- 238000011282 treatment Methods 0.000 title claims 4
- 208000023504 respiratory system disease Diseases 0.000 title claims 2
- 239000003814 drug Substances 0.000 claims 14
- 229940079593 drug Drugs 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 8
- 208000018569 Respiratory Tract disease Diseases 0.000 claims 6
- 208000006673 asthma Diseases 0.000 claims 4
- 201000010105 allergic rhinitis Diseases 0.000 claims 3
- 239000006184 cosolvent Substances 0.000 claims 3
- -1 cyclohexylmethylene Chemical group 0.000 claims 3
- 239000003380 propellant Substances 0.000 claims 3
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 claims 2
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 208000036284 Rhinitis seasonal Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000008249 pharmaceutical aerosol Substances 0.000 claims 2
- 210000002345 respiratory system Anatomy 0.000 claims 2
- 206010039083 rhinitis Diseases 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical group O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 1
- 206010003557 Asthma exercise induced Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- QIEPWCSVQYUPIY-LEKSSAKUSA-N Delta(1)-progesterone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 QIEPWCSVQYUPIY-LEKSSAKUSA-N 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000004657 Exercise-Induced Asthma Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000037656 Respiratory Sounds Diseases 0.000 claims 1
- 206010047924 Wheezing Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 239000008365 aqueous carrier Substances 0.000 claims 1
- 239000013011 aqueous formulation Substances 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 125000000837 carbohydrate group Chemical group 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000024695 exercise-induced bronchoconstriction Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 229960001021 lactose monohydrate Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 239000007923 nasal drop Substances 0.000 claims 1
- 208000024696 nocturnal asthma Diseases 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000017022 seasonal allergic rhinitis Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Claims (30)
1. Uporaba ciklesonida, njegove farmaceutski prihvatljive soli, njegovih solvata ili njegovih fiziološki učinkovitih derivata, naznačena time, da je za proizvodnju lijeka za liječenje ili prevenciju bolesti dišnih puteva kod pacijenta, dok pacijent je dijete, pri čemu se smanjuje ili izbjegava pojačanje zagušenja koje je popratna pojava povezana s inhaliranim i intranazalno unesenim kortikosteroidima, te pri čemu se lijek primjenjuje u dozi od 20 do 200 μg ciklesonida.
2. Uporaba prema zahtjevu 1, naznačena time, da dijete je čovjek u predpubertetu.
3. Uporaba prema zahtjevu 1, naznačena time, da dijete je čovjek u dobi od 6 do 12 godina.
4. Uporaba prema zahtjevu 1, naznačena time, da se lijek primjenjuje u dozi od 20, 40, 60, 80, 100, 120, 140, 160, 180 ili 200 μg ciklesonida.
5. Uporaba prema zahtjevu 1, naznačena time, da se lijek primjenjuje u dozi od 40, 80, 160 μg ciklesonida.
6. Uporaba prema zahtjevu 1, naznačena time, da doza lijeka je dnevna doza u stalnom režimu liječenja.
7. Uporaba prema zahtjevu 6, naznačena time, da razdoblje liječenja je dulje od jednog dana.
8. Uporaba prema zahtjevu 7, naznačena time, da razdoblje liječenja je dulje od jednog tjedna.
9. Uporaba prema zahtjevu 1, naznačena time, da ona nema utjecaja na brzinu rasta pacijenta.
10. Uporaba prema zahtjevu 1, naznačena time, da lijek sadrži farmaceutski prihvatljiv nosač i/ili jedno ili više pomoćnih sredstava.
11. Uporaba prema zahtjevu 1, naznačena time, da je ciklesonid odabran iz sljedeće skupine:
[11β,16α-(R)]-16,17-[(cikloheksilmetilen)bis(oksi)]-11-hidroksi-21-(2-metil-1-oksopropoksi)pregna-1,4-dien-3,20-dion,
[11β,16α-(S)]-16,17-[(cikloheksilmetilen)bis(oksi)]-11-hidroksi-21-(2-metil-1-oksopropoksi)pregna-1,4-dien-3,20-dion,
[11β,16α-(R,S)]-16,17-[(cikloheksilmetilen)bis(oksi)]-11-hidroksi-21-(2-metil-1-oksopropoksi)pregna-1,4-dien-3,20-dion,
16α,17-(22R)-cikloheksilmetilendioksi-11β,21-dihidroksipregna-1,4-dien-3,20-dion,
16α,17-(22S)-cikloheksilmetilendioksi-11β,21-dihidroksipregna-1,4-dien-3,20-dion, i
16α,17-(22R,S)-cikloheksilmetilendioksi-11β,21-dihidroksipregna-1,4-dien-3,20-dion.
12. Uporaba prema zahtjevu 1, 4 ili 5, naznačena time, da doza lijeka je dnevna doza koja se primjenjuje jednom dnevno.
13. Uporaba prema zahtjevu 1, naznačena time, da je lijek prikladan za primjenu putem inhalacije.
14. Uporaba prema zahtjevu 13, naznačena time, da sastav lijeka je farmaceutska aerosolna formulacija koja sadrži djelotvornu količinu ciklesonida i hidrofluorokarbonski stlačeni plin (propelant), poželjno odabran od 1,1,1,2-tetrafluoroetana, 1,1,1,2,3,3,3-heptafluoropropana i njihovih mješavina, te kootapalo u djelotvornoj količini za rastapanje ciklesonida i opcijski tenzida.
15. Uporaba prema zahtjevu 14, naznačena time, da kootapalo je etanol.
16. Uporaba prema zahtjevu 13, naznačena time, da sastav lijeka je farmaceutska aerosolna formulacija koja sadrži čestice ciklesonida u terapeutski djelotvornoj količini i hidrofluorokarbonski stlačeni plin (propelant), poželjno odabran od 1,1,1,2-tetrafluoroetana, 1,1,1,2,3,3,3-heptafluoropropana i njihovih mješavina, te polarno kootapalo i opcijski tenzid u količini od 0,01 do 5 masenih % prema masi propelanta.
17. Uporaba prema zahtjevu 13, naznačena time, da sastav lijeka je suhi prašak i nosač je saharid.
18. Uporaba prema zahtjevu 13, naznačena time, da nosač je monohidrat laktoze.
19. Uporaba prema zahtjevu 1, naznačena time, da je bolest dišnih puteva odabrana iz skupine koju čine astma, noćna astma, astma inducirana napornom vježbom, kronična opstrukcijska plućna bolest (COPD), kronični i hripavi bronhitis, emfizem, upala respiratornog trakta i bolest gornjeg respiratornog trakta, rinitis, alergijski i sezonski rinitis.
20. Uporaba prema zahtjevu 1, naznačena time, da bolest dišnih puteva je slaba ili prosječna astma.
21. Uporaba prema zahtjevu 1, naznačena time, da se ciklesonid uglavnom sastoji od R-epimera.
22. Uporaba prema zahtjevu 1, naznačena time, da lijek je intranazalni sprej ili su to kapi za nos.
23. Uporaba prema zahtjevu 22, naznačena time, da lijek je vodena formulacija za primjenu na sluznicu.
24. Uporaba prema zahtjevu 22, naznačena time, da lijek je formuliran s ne-vodenim nosačima.
25. Uporaba prema zahtjevu 1, naznačena time, da bolest dišnih puteva je rinitis.
26. Uporaba prema zahtjevu 1, naznačena time, da bolest dišnih puteva je alergijski rinitis.
27. Uporaba prema zahtjevu 1, naznačena time, da bolest dišnih puteva je sezonski alergijski rinitis.
28. Uporaba prema zahtjevu 1, naznačena time, da dijete je čovjek u dobi ispod 18 godina.
29. Uporaba prema zahtjevu 1, 4 ili 5, naznačena time, da se primjenjuje količina ciklesonida kao dnevna doza.
30. Uporaba prema zahtjevu 15, naznačena time, da bolest dišnih puteva je astma, pri kojoj se doza sastava primjenjuje jednom dnevno, a sadrži 40, 80 ili 160 µg ciklesonida.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50298403P | 2003-09-16 | 2003-09-16 | |
| EP04766791.0A EP1670482B2 (en) | 2003-09-16 | 2004-09-15 | Use of ciclesonide for the treatment of respiratory diseases |
| PCT/EP2004/052172 WO2005025578A1 (en) | 2003-09-16 | 2004-09-15 | Use of ciclesonide for the treatment of respiratory diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20140257T1 true HRP20140257T1 (hr) | 2014-04-25 |
| HRP20140257T4 HRP20140257T4 (hr) | 2022-11-25 |
Family
ID=34312429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140257TT HRP20140257T4 (hr) | 2003-09-16 | 2014-03-18 | Uporaba ciklesonida za liječenje bolesti dišnih puteva |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US8371292B2 (hr) |
| EP (1) | EP1670482B2 (hr) |
| JP (2) | JP5618452B2 (hr) |
| AU (1) | AU2004271744B2 (hr) |
| CA (1) | CA2538419C (hr) |
| DK (1) | DK1670482T4 (hr) |
| ES (1) | ES2452691T5 (hr) |
| HR (1) | HRP20140257T4 (hr) |
| PL (1) | PL1670482T5 (hr) |
| PT (1) | PT1670482E (hr) |
| WO (1) | WO2005025578A1 (hr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1572217T3 (da) * | 2002-12-12 | 2008-12-15 | Nycomed Gmbh | Kombinationsmedikament af R,R-formoterol og ciclesonid |
| DK1670482T4 (da) | 2003-09-16 | 2022-08-22 | Covis Pharma B V | Anvendelse af ciclesonid til behandlingen af respiratoriske sygdomme |
| PE20050941A1 (es) * | 2003-12-16 | 2005-11-08 | Nycomed Gmbh | Suspensiones acuosas de ciclesonida para nebulizacion |
| WO2005082413A2 (en) * | 2004-02-27 | 2005-09-09 | Altana Pharma Ag | Ciclesonide and glycopyrronium combination |
| US20070134165A1 (en) * | 2004-04-20 | 2007-06-14 | Altana Pharma Ag | Use of Ciclesonide for the Treatment of Respiratory Disease in a Smoking Patient |
| CA2637815A1 (en) * | 2006-02-08 | 2007-08-16 | Sicor Inc. | Crystalline forms of ciclesonide |
| WO2009052624A1 (en) * | 2007-10-25 | 2009-04-30 | Merck Frosst Canada Ltd. | Combination therapy |
| ES2471145T3 (es) * | 2009-03-09 | 2014-06-25 | Mikasa Seiyaku Co,. Ltd. | Compuesto esteroide |
| EP2744479A1 (en) | 2011-08-18 | 2014-06-25 | Takeda GmbH | Pharmaceutical aerosol product for administration by oral or nasal inhalation |
| EP3473255B1 (en) * | 2012-12-21 | 2022-01-12 | Boehringer Ingelheim Vetmedica GmbH | Pharmaceutical formulation comprising ciclesonide |
| RS57740B1 (sr) | 2012-12-21 | 2018-12-31 | Boehringer Ingelheim Vetmedica Gmbh | Ciklezonid za lečenje oboljenja disajnih puteva kod konja |
| PL3157522T3 (pl) | 2014-06-18 | 2020-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Antagonisty muskarynowi i ich kombinacje do leczenia choroby dróg oddechowych u koni |
| EP3432954B1 (en) * | 2016-03-24 | 2022-04-20 | Services Medicaux Arnold et Joan Zidulka Inc. | Device for delivering particles in the upper respiratory tract |
| CA3025377A1 (en) | 2016-06-02 | 2017-12-07 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
| PL3658192T3 (pl) | 2017-12-01 | 2021-10-18 | Abbvie Inc. | Agonista receptora glukokortykoidowego i jego immunokoniugaty |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE9716T1 (de) | 1980-02-27 | 1984-10-15 | Tate & Lyle Public Limited Company | Kristalline glukose und verfahren zu deren herstellung. |
| US4816445A (en) | 1984-06-21 | 1989-03-28 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Crystalline alpha-maltose |
| JP2518646B2 (ja) | 1987-05-29 | 1996-07-24 | 株式会社 林原生物化学研究所 | マルト−ス粉末の製造方法 |
| GB8828477D0 (en) | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| ATE111364T1 (de) | 1989-05-31 | 1994-09-15 | Fisons Plc | Medikament und inhalationsvorrichtung dafür. |
| GB8921222D0 (en) | 1989-09-20 | 1989-11-08 | Riker Laboratories Inc | Medicinal aerosol formulations |
| SE8903914D0 (sv) | 1989-11-22 | 1989-11-22 | Draco Ab | Oral composition for the treatment of inflammatory bowel diseases |
| IE67185B1 (en) | 1990-02-02 | 1996-03-06 | Fisons Plc | Propellant compositions |
| DE4003272A1 (de) | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen |
| US6536427B2 (en) | 1990-03-02 | 2003-03-25 | Glaxo Group Limited | Inhalation device |
| US5178866A (en) | 1990-03-23 | 1993-01-12 | Alza Corporation | Dosage form for delivering drug to the intestine |
| JPH05505824A (ja) | 1990-03-23 | 1993-08-26 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | 所定投与量エアロゾル製剤の製造のための可溶性弗素界面活性剤の使用 |
| GR1001529B (el) | 1990-09-07 | 1994-03-31 | Elmuquimica Farm Sl | Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης. |
| US5434304A (en) | 1990-09-26 | 1995-07-18 | Aktiebolaget Astra | Process for preparing formoterol and related compounds |
| JP2769925B2 (ja) | 1990-10-18 | 1998-06-25 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | ベクロメタゾン１７，２１ジプロピオネートを含んで成るエアロゾル製剤 |
| US5290539A (en) | 1990-12-21 | 1994-03-01 | Minnesota Mining And Manufacturing Company | Device for delivering an aerosol |
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| US5795564A (en) | 1991-04-05 | 1998-08-18 | Sepracor, Inc. | Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol |
| US6866839B2 (en) | 1991-04-05 | 2005-03-15 | Sepracor Inc. | Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol |
| EP0656207B2 (en) | 1991-06-10 | 2009-07-22 | Schering Corporation | Non-chlorofluorocarbon aerosol formulations |
| IT1250691B (it) | 1991-07-22 | 1995-04-21 | Giancarlo Santus | Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac. |
| IL104068A (en) | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant |
| GB9213874D0 (en) | 1992-06-30 | 1992-08-12 | Fisons Plc | Process to novel medicament form |
| GB9306703D0 (en) | 1993-03-31 | 1993-05-26 | Fisons Plc | Inhalation device |
| ES2124884T3 (es) | 1993-04-02 | 1999-02-16 | Byk Gulden Lomberg Chem Fab | Nuevos derivados de prednisolona. |
| US5476411A (en) | 1993-07-16 | 1995-12-19 | Henkel Corporation | Aqueous composition for wet sanding of dried paint, plastics, and the like |
| IL111194A (en) | 1993-10-08 | 1998-02-08 | Fisons Plc | Process for the production of drug patramulations |
| DE4434629C1 (de) * | 1994-09-28 | 1996-06-27 | Byk Gulden Lomberg Chem Fab | Zusammensetzungen zur Behandlung von IRDS und ARDS |
| DE19541689A1 (de) | 1994-11-14 | 1996-05-15 | Byk Gulden Lomberg Chem Fab | Kombinationsarzneimittel |
| ATE250439T1 (de) | 1995-04-14 | 2003-10-15 | Smithkline Beecham Corp | Dosierinhalator für salmeterol |
| US5811388A (en) | 1995-06-07 | 1998-09-22 | Cibus Pharmaceutical, Inc. | Delivery of drugs to the lower GI tract |
| EP0833622B8 (en) | 1995-06-12 | 2005-10-12 | G.D. Searle & Co. | Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor |
| US5840917A (en) | 1995-09-26 | 1998-11-24 | Takeda Chemical Industries, Ltd. | Phosphorylamides, their preparation and use |
| DE19635498A1 (de) | 1996-09-03 | 1998-03-26 | Byk Gulden Lomberg Chem Fab | Verfahren zur Epimerenanreicherung |
| SE9603725D0 (sv) | 1996-10-11 | 1996-10-11 | Astra Ab | New teatment |
| US6380222B2 (en) | 1996-10-11 | 2002-04-30 | Astrazeneca Ab | Use of an H+, K+-atpase inhibitor in the treatment of nasal polyps |
| FR2754712B1 (fr) | 1996-10-17 | 1999-09-03 | Merck Sharp Dohme Chibret Lab | Compositions ophtalmiques |
| US6040344A (en) | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
| US6613795B2 (en) | 1996-11-11 | 2003-09-02 | Christian Noe | Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments |
| SE9700135D0 (sv) | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| US20020111495A1 (en) | 1997-04-04 | 2002-08-15 | Pfizer Inc. | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes |
| US6120752A (en) | 1997-05-21 | 2000-09-19 | 3M Innovative Properties Company | Medicinal aerosol products containing formulations of ciclesonide and related steroids |
| GB2329939A (en) | 1997-06-26 | 1999-04-07 | Glaxo Group Ltd | Self-lubricating valve stem for aerosol containers |
| US6470894B2 (en) | 1997-09-19 | 2002-10-29 | Thione International, Inc. | Glutathione, green tea, grape seed extract to neutralize tobacco free radicals |
| SE9704186D0 (sv) | 1997-11-14 | 1997-11-14 | Astra Ab | New composition of matter |
| ES2308821T3 (es) | 1997-12-15 | 2008-12-01 | Astellas Pharma Inc. | Nuevos derivados de pirimidin-5-carboxamida. |
| SE9801368D0 (sv) | 1998-04-20 | 1998-04-20 | Astra Ab | New use |
| TWI243687B (en) | 1998-04-21 | 2005-11-21 | Teijin Ltd | Pharmaceutical composition for application to mucosa |
| US6264923B1 (en) * | 1998-05-13 | 2001-07-24 | 3M Innovative Properties Company | Medicinal aerosol formulation of ciclesonide and related compounds |
| US6241969B1 (en) | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
| ES2234266T3 (es) | 1998-07-24 | 2005-06-16 | Jago Research Ag | Formulaciones medicas para aerosoles. |
| US6475467B1 (en) | 1998-08-04 | 2002-11-05 | Jago Research Ag | Medicinal aerosol formulations |
| ES2191464T3 (es) | 1998-09-23 | 2003-09-01 | Altana Pharma Ag | Tetrahidropiridoeteres. |
| US6645466B1 (en) | 1998-11-13 | 2003-11-11 | Jago Research Ag | Dry powder for inhalation |
| US6352152B1 (en) | 1998-12-18 | 2002-03-05 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
| US6397838B1 (en) | 1998-12-23 | 2002-06-04 | Battelle Pulmonary Therapeutics, Inc. | Pulmonary aerosol delivery device and method |
| US6124268A (en) | 1999-02-17 | 2000-09-26 | Natreon Inc. | Natural antioxidant compositions, method for obtaining same and cosmetic, pharmaceutical and nutritional formulations thereof |
| KR20020003239A (ko) | 1999-04-23 | 2002-01-10 | 추후기재 | 방향제어식 수중방전충격 동적 에어러솔 분무기 |
| EP1171243B1 (en) | 1999-04-23 | 2006-08-16 | Ventaira Pharmaceuticals, Inc. | High mass transfer electrosprayer |
| JP2001048807A (ja) | 1999-08-04 | 2001-02-20 | Wakamoto Pharmaceut Co Ltd | 難溶性薬物を水に溶解してなる製剤 |
| DE19947234A1 (de) | 1999-09-30 | 2001-04-05 | Asta Medica Ag | Neue Kombination von Loteprednol und Antihistaminika |
| AR026073A1 (es) | 1999-10-20 | 2002-12-26 | Nycomed Gmbh | Composicion farmaceutica acuosa que contiene ciclesonida |
| AR026072A1 (es) | 1999-10-20 | 2002-12-26 | Nycomed Gmbh | Composicion farmaceutica que contiene ciclesonida para aplicacion a la mucosa |
| GB0002336D0 (en) | 2000-02-01 | 2000-03-22 | Glaxo Group Ltd | Medicaments |
| US7585847B2 (en) * | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
| GB0009607D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Medical compositions |
| GB0012261D0 (en) | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel process |
| GB0015043D0 (en) | 2000-06-21 | 2000-08-09 | Glaxo Group Ltd | Medicament dispenser |
| TWI227231B (en) * | 2000-07-12 | 2005-02-01 | Novartis Ag | 4-benzoyl-piperidine derivatives for treating conditions mediated by CCR-3 |
| FI20002177A0 (fi) | 2000-10-02 | 2000-10-02 | Orion Yhtymae Oyj | Uusi yhdistelmä astman hoitoon |
| CZ2003983A3 (cs) | 2000-10-09 | 2003-09-17 | 3M Innovative Properties Company | Léčivé aerosolové přípravky |
| DE10062712A1 (de) * | 2000-12-15 | 2002-06-20 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden |
| US20020183292A1 (en) | 2000-10-31 | 2002-12-05 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and corticosteroids |
| AU2002227123A1 (en) | 2000-11-07 | 2002-05-21 | Merck And Co., Inc. | Method of treatment with a combination of a pde4 inhibitor and a leukotriene antagonist |
| AU2002222304B2 (en) | 2000-12-22 | 2004-03-18 | Glaxo Group Limited | Metered dose inhaler for salmeterol xinafoate |
| WO2003006310A1 (fr) | 2001-07-13 | 2003-01-23 | Tfe Techniques Et Fabrications Electroniques | Dispositif destine a indiquer acoustiquement a un plongeur equipe d'un scaphandre la pression de gaz de respiration dans le reservoir et/ou la pression hydrostatique |
| JP2005508220A (ja) | 2001-10-24 | 2005-03-31 | パーリ・ゲーエムベーハー | 薬用組成物調製用具 |
| JP4571802B2 (ja) | 2001-11-17 | 2010-10-27 | アベンティス・フアーマ・リミテッド | 吸着剤及びその使用 |
| EP1453493A2 (en) | 2001-11-19 | 2004-09-08 | ALTANA Pharma AG | Reversible proton pump inhibitors for the treatment of airway disorders |
| ITMI20020808A1 (it) | 2002-04-17 | 2003-10-17 | Chiesi Farma Spa | Procedimento per la preparazione di una sospensione sterile di particelle di beclometasone dipropionato da somministrare per inalazione |
| JP4559221B2 (ja) | 2002-07-02 | 2010-10-06 | ニコメド ゲゼルシャフト ミット ベシュレンクテル ハフツング | シクレソニド含有無菌水性懸濁製剤 |
| DK1572217T3 (da) | 2002-12-12 | 2008-12-15 | Nycomed Gmbh | Kombinationsmedikament af R,R-formoterol og ciclesonid |
| EP1452179A1 (en) * | 2003-02-27 | 2004-09-01 | CHIESI FARMACEUTICI S.p.A. | Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid |
| DK1670482T4 (da) | 2003-09-16 | 2022-08-22 | Covis Pharma B V | Anvendelse af ciclesonid til behandlingen af respiratoriske sygdomme |
-
2004
- 2004-09-15 DK DK04766791.0T patent/DK1670482T4/da active
- 2004-09-15 PT PT47667910T patent/PT1670482E/pt unknown
- 2004-09-15 PL PL04766791.0T patent/PL1670482T5/pl unknown
- 2004-09-15 CA CA2538419A patent/CA2538419C/en not_active Expired - Fee Related
- 2004-09-15 JP JP2006525842A patent/JP5618452B2/ja active Active
- 2004-09-15 WO PCT/EP2004/052172 patent/WO2005025578A1/en active Application Filing
- 2004-09-15 EP EP04766791.0A patent/EP1670482B2/en active Active
- 2004-09-15 AU AU2004271744A patent/AU2004271744B2/en active Active
- 2004-09-15 US US10/571,311 patent/US8371292B2/en active Active
- 2004-09-15 ES ES04766791T patent/ES2452691T5/es active Active
-
2012
- 2012-06-18 JP JP2012137341A patent/JP2012197306A/ja active Pending
-
2013
- 2013-01-18 US US13/744,962 patent/US20130143849A1/en not_active Abandoned
-
2014
- 2014-03-18 HR HRP20140257TT patent/HRP20140257T4/hr unknown
-
2019
- 2019-06-13 US US16/440,557 patent/US20190290661A1/en not_active Abandoned
-
2021
- 2021-09-10 US US17/447,302 patent/US20220241297A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1670482A1 (en) | 2006-06-21 |
| EP1670482B1 (en) | 2013-12-25 |
| US20190290661A1 (en) | 2019-09-26 |
| US20070025923A1 (en) | 2007-02-01 |
| DK1670482T3 (en) | 2014-03-17 |
| CA2538419A1 (en) | 2005-03-24 |
| US8371292B2 (en) | 2013-02-12 |
| CA2538419C (en) | 2012-07-03 |
| PT1670482E (pt) | 2014-03-12 |
| JP2012197306A (ja) | 2012-10-18 |
| PL1670482T5 (pl) | 2022-10-03 |
| JP2007505829A (ja) | 2007-03-15 |
| US20130143849A1 (en) | 2013-06-06 |
| ES2452691T3 (es) | 2014-04-02 |
| WO2005025578A1 (en) | 2005-03-24 |
| AU2004271744B2 (en) | 2010-07-29 |
| JP5618452B2 (ja) | 2014-11-05 |
| DK1670482T4 (da) | 2022-08-22 |
| US20220241297A1 (en) | 2022-08-04 |
| PL1670482T3 (pl) | 2014-05-30 |
| AU2004271744A1 (en) | 2005-03-24 |
| EP1670482B2 (en) | 2022-06-29 |
| HRP20140257T4 (hr) | 2022-11-25 |
| ES2452691T5 (es) | 2022-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140257T1 (hr) | Uporaba ciklesonida za lijeäśenje bolesti dišnih puteva | |
| NO328698B1 (no) | Anvendelse av mometasonfuroat for fremstilling av et torrpulverinhaleringsmedikament for behandling av sykdommer i de ovre eller nedre luftveier eller lunger | |
| US20070020190A1 (en) | Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients | |
| CN107998109A (zh) | 药物组合物 | |
| JP2004500433A (ja) | チオトロピウムとブデソニドを含む組合せ医薬 | |
| JP2007505829A5 (hr) | ||
| JP2007524698A5 (hr) | ||
| Edsbäcker | Pharmacological factors that influence the choice of inhaled corticosteroids | |
| US20090022671A1 (en) | Treatment methods | |
| Mealy et al. | Ciclesonide | |
| Wu et al. | Pulmonary and nasal anti-inflammatory and anti-allergy inhalation aerosol delivery systems | |
| JP2007533706A5 (hr) | ||
| WO2006097458A1 (en) | Novel combination | |
| Pavord et al. | Pharmacokinetic optimisation of inhaled steroid therapy in asthma | |
| Fabbri et al. | Oral vs inhaled asthma therapy: Pros, cons and combinations | |
| US20060134009A1 (en) | Low dose corticosteroid powders for inhalation | |
| Sorbera et al. | Fluticasone furoate | |
| RU2678992C2 (ru) | Фармацевтическая композиция, содержащая арформотерол и флутиказона фуроат | |
| US9636350B2 (en) | Pharmaceutical composition for use in nasal administration containing corticoid, and a quinolone or fusidic acid | |
| JP5220741B2 (ja) | アンドラスト／グルココルチコイドの併用 | |
| US20130125882A1 (en) | Method and composition for treating asthma and copd | |
| JP2013056925A (ja) | アンドラスト／グルココルチコイドの併用 |